Daily 500 mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients with Multiple Myeloma Treated with Bortezomib

TOSHIHIRO FUKUSHIMA; TOMOMI SATO; TAKUJI NAKAMURA; HARUKA IWAO; AKIO NAKAJIMA; MIYUKI MIKI; TOMOYUKI SAKAI; TAKAFUMI KAWANAMI; TOSHIOKI SAWAKI; YOSHIMASA FUJITA; MASAO TANAKA; YASUFUMI MASAKI; TOSHIRO OKAZAKI; HIDEO NAKAJIMA; YOSHIHARU MOTOO; HISANORI UMEHARA

Research ArticleClinical Studies

Daily 500 mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients with Multiple Myeloma Treated with Bortezomib

TOSHIHIRO FUKUSHIMA, TOMOMI SATO, TAKUJI NAKAMURA, HARUKA IWAO, AKIO NAKAJIMA, MIYUKI MIKI, TOMOYUKI SAKAI, TAKAFUMI KAWANAMI, TOSHIOKI SAWAKI, YOSHIMASA FUJITA, MASAO TANAKA, YASUFUMI MASAKI, TOSHIRO OKAZAKI, HIDEO NAKAJIMA, YOSHIHARU MOTOO and HISANORI UMEHARA

Anticancer Research December 2012, 32 (12) 5437-5440;

TOSHIHIRO FUKUSHIMA

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: tfukus{at}kanazawa-med.ac.jp

TOMOMI SATO

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKUJI NAKAMURA

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HARUKA IWAO

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

AKIO NAKAJIMA

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MIYUKI MIKI

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOMOYUKI SAKAI

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKAFUMI KAWANAMI

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIOKI SAWAKI

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOSHIMASA FUJITA

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MASAO TANAKA

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YASUFUMI MASAKI

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIRO OKAZAKI

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIDEO NAKAJIMA

2Department of Medical Oncology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOSHIHARU MOTOO

2Department of Medical Oncology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HISANORI UMEHARA

1Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Tables

PreviousNext

In this issue

Anticancer Research

Vol. 32, Issue 12

December 2012

Table of Contents
Table of Contents (PDF)
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Daily 500 mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients with Multiple Myeloma Treated with Bortezomib

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 3 + 9 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Daily 500 mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients with Multiple Myeloma Treated with Bortezomib

Anticancer Research Dec 2012, 32 (12) 5437-5440;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Daily 500 mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients with Multiple Myeloma Treated with Bortezomib

Anticancer Research Dec 2012, 32 (12) 5437-5440;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

Importance of Compliance With Guidelines for the Prevention of Varicella-Zoster Virus Reactivation in Multiple Myeloma
Prophylactic Efficacy Against Herpes Zoster and Costs Difference Between Acyclovir and Valaciclovir in Hematological Patients
Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects

Google Scholar

Keywords

multiple myeloma
Bortezomib
varicella zoster virus
valacyclovir
acyclovir

Main menu

User menu

Search

Daily 500 mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients with Multiple Myeloma Treated with Bortezomib

Article Figures & Data

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords